<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03922932</url>
  </required_header>
  <id_info>
    <org_study_id>OHSU IRB#00016932</org_study_id>
    <nct_id>NCT03922932</nct_id>
  </id_info>
  <brief_title>WF and PR OCTA in Diabetic Retinopathy</brief_title>
  <official_title>Wide-Field and Projection-Resolved Optical Coherence Tomography Angiography in Diabetic Retinopathy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Oregon Health and Science University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Oregon Health and Science University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Diabetic retinopathy (DR) is a leading cause of vision loss in working-age Americans.
      Capillary damage from hyperglycemia causes vision loss through downstream effects, such as
      retinal ischemia, edema, and neovascularization (NV). Proper screening and timely treatment
      with laser photocoagulation and anti-vascular endothelial growth factor (VEGF) injections can
      minimize morbidity. In the last decade, clinicians have been able to use objective structural
      data from optical coherence tomography (OCT) to guide the treatment of diabetic macular
      edema. Other aspects of care, however, still largely depend on subjective interpretation of
      clinical features and fluorescein angiography (FA) to determine the disease severity and
      treatment threshold. The recently developed OCT angiography (OCTA) provides dye-less,
      injection-free, three-dimensional images of the retinal and choroidal circulation with high
      capillary contrast. Not only is it safer, faster, and less expensive than conventional
      dye-based angiography, OCTA provides the potential of giving clinicians objective tools for
      determining severity of disease by detecting and quantifying NV and non-perfusion.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 30, 2017</start_date>
  <completion_date type="Anticipated">December 2023</completion_date>
  <primary_completion_date type="Anticipated">December 2023</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>PR-OCTA Measure of Non-Perfusion Areas</measure>
    <time_frame>3 years</time_frame>
    <description>Non-perfusion areas of the 3 retinal plexuses and choriocapillaris will be measured in mm2.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Non-PR-OCTA Measure of Retinal Non-Perfusion Areas</measure>
    <time_frame>1 year</time_frame>
    <description>Non-perfusion areas of the 3 retinal plexuses will be measured in mm2.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Non-PR-OCTA Retinal Neovascularization Areas</measure>
    <time_frame>1 year</time_frame>
    <description>Retinal neovascularization areas will be measured in mm2.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Structural OCT Cyst Volume</measure>
    <time_frame>1 year</time_frame>
    <description>Cyst volume will be measured in mm3.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Structural OCT Retinal Thickening Area</measure>
    <time_frame>1 year</time_frame>
    <description>The area of retinal thickening will be measured in mm2.</description>
  </primary_outcome>
  <number_of_groups>5</number_of_groups>
  <enrollment type="Anticipated">290</enrollment>
  <condition>Diabetic Retinopathy</condition>
  <arm_group>
    <arm_group_label>Group A: PDR</arm_group_label>
    <description>This group will consist of 25 subjects with active proliferative diabetic retinopathy (PDR) and 25 subjects with treated PDR.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group B: NPDR</arm_group_label>
    <description>This group will consist of 50 subjects with severe non-proliferative diabetic retinopathy (NPDR), 50 subjects with moderate NPDR, and 50 subjects with mild NPDR.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group ME: Macular Edema</arm_group_label>
    <description>This group is a sub-set of 25 subjects from either Group A or B who have macular edema requiring treatment.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group C: DM without Retinopathy</arm_group_label>
    <description>This group will consist of 50 subjects with diabetes mellitus (DM) who do not have retinopathy.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group D: Healthy Controls</arm_group_label>
    <description>This group will consist of 40 subjects with healthy eyes who do not have diabetes.</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Adults age 18 or older with either healthy eyes or diabetic retinopathy
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Participant-Related Inclusion Criteria:

        I. All Diabetics (Groups A, B, C)

          -  Type 1 diabetes of at least 5 years duration or

          -  Type 2 diabetes of any duration II. Group B

          -  Able to return for follow-up over 3 years

        Participant-Related Exclusion Criteria:

        I. Group B

          -  Significant medical condition that would make long-term follow-up difficult II.
             Controls (Group D)

          -  Any medical problems associated with retinal vascular abnormalities (i.e.,
             hypertension, systemic vasculitis, carotid insufficiency, etc.)

        Eye-Related Inclusion Criteria:

        I. Group A:

          -  Presence of active neovascularization, with or without prior treatment

          -  Presence of involuted fibrovascular proliferans

        II. Group B:

          -  NPDR of any severity as defined by the International Clinical Diabetic Retinopathy
             Severity Scale

        III. Groups C &amp; D:

          -  No evidence of diabetic retinopathy

        IV. Group ME:

          -  Presence of center-involving macular edema requiring treatment

        Eye-Related Exclusion Criteria: (Applies to study eye only. May be present in non-study
        eye.)

          -  Visual acuity worse than 20/200

          -  Inability to maintain stable fixation for OCT imaging

          -  History of major eye surgery (vitrectomy, cataract surgery, scleral buckle, other
             intraocular surgery, etc.) within 90 days of enrollment

          -  History of another eye disease or condition that may alter retinal perfusion,
             permeability, or retinal anatomy

          -  Substantial media opacity (cataract, corneal scar, vitreous hemorrhage) that may
             interfere with study imaging
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Thomas Hwang, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Oregon Health and Science University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>David Poole, COT</last_name>
    <phone>503-494-8024</phone>
    <email>pooleb@ohsu.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Denny Romfh, OD</last_name>
    <phone>503-494-4351</phone>
    <email>romfhd@ohsu.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Oregon Health &amp; Science University</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97239</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>David Poole, COT</last_name>
      <phone>503-494-8024</phone>
      <email>pooleb@ohsu.edu</email>
    </contact>
    <contact_backup>
      <last_name>Denny Romfh, OD</last_name>
      <phone>503-494-4351</phone>
      <email>romfhd@ohsu.edu</email>
    </contact_backup>
    <investigator>
      <last_name>David Wilson, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Andreas Lauer, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Steve Bailey, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Phoebe Lin, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>John P Campbell, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Christina Flaxel, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Kavita Bhavsar, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Matthew Duggan, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Rene Choi, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Stanford Taylor, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>April 18, 2019</study_first_submitted>
  <study_first_submitted_qc>April 18, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">April 22, 2019</study_first_posted>
  <last_update_submitted>April 8, 2020</last_update_submitted>
  <last_update_submitted_qc>April 8, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 9, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Oregon Health and Science University</investigator_affiliation>
    <investigator_full_name>David Huang</investigator_full_name>
    <investigator_title>Thomas Hwang, MD, Associate Professor of Ophthalmology</investigator_title>
  </responsible_party>
  <keyword>Diabetes</keyword>
  <keyword>OCT</keyword>
  <keyword>Angiography</keyword>
  <keyword>Diabetic retinopathy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Retinal Diseases</mesh_term>
    <mesh_term>Diabetic Retinopathy</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

